Overall, we posit that novel potential biomarkers such as α‐syn and/or DJ‐1 may help diagnose patients with early‐stage melanoma, who are likely to develop advanced metastatic disease and would benefit from additional therapies. This evidence concerns the gene PARK7 and metastatic neoplasm.